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Abstract
Background: We sought to investigate the prognostic value of volumetric positron
emission tomography (PET) parameters in patients with human papillomavirus
(HPV)-related oropharyngeal squamous cell carcinoma (OPSCC) and a ≤10 pack-
year smoking history treated with chemoradiation.
Methods: A total of 142 patients were included. Maximum standardized uptake
value, metabolic tumor volume, and total lesion glycolysis (TLG) of the primary
tumor, involved regional lymph nodes, and total lesion were calculated. Cox pro-
portional hazard modeling was used to evaluate associations of clinical and PET
parameters with locoregional failure-free survival (LRFFS), distant metastasis-free
survival (DMFS), and overall survival (OS).
Results: On univariate analysis, volumetric PET parameters were significantly
associated with all endpoints, and 8th edition American Joint Committee on Can-
cer/Union Internationale Contre le Cancer staging was significantly associated with
DMFS and OS. On multivariate analysis, total lesion TLG was significantly associ-
ated with LRFFS, while staging was most significantly prognostic for DMFS
and OS.
Conclusion: Volumetric PET parameters are uniquely prognostic of LRFFS in
low-risk HPV-related OPSCC and may be useful for directing de-intensification
strategies.
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1 | INTRODUCTION
Human papillomavirus (HPV)-related oropharyngeal squa-
mous cell carcinoma (OPSCC) has increased in incidence in
recent years1 and is associated with a better prognosis than
tobacco-related OPSCC.2 Despite its better prognosis, stan-
dard treatment of HPV-related OPSCC is the same as for
tobacco-related OPSCC, and may produce substantial com-
plications that reduce the quality of life in cancer survivors.3
To reduce these complications, several reported and ongoing
studies have attempted to de-intensify treatments in HPV-
related OPSCC.4 However, appropriate patient selection for
treatment de-intensification is vital in order to not jeopardize
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the chance for cure. While de-intensification strategies
uniformly stipulate HPV-positivity for inclusion, there is
variability in the consideration of other factors such as
smoking history and TNM classifications.5 Reanalysis of
RTOG 0129 established HPV-related OPSCC patients
with smoking history ≤10 pack-years to have the most
favorable prognosis, thus potentially making them good
candidates for treatment de-intensification.2 Recent pro-
spective trials investigating de-intensified concurrent che-
moradiation in HPV-related OPSCC patients have
demonstrated high rates of tumor control and survival in
patients with minimal smoking history.6–9 Further disease
classification within this group could lead to more precise
individualized treatment.
The recently updated 8th Edition (Ed.) of the American
Joint Committee on Cancer (AJCC) Cancer Staging
Manual has incorporated a novel staging system for HPV-
related OPSCC.10 This staging system was based on 2 land-
mark studies that demonstrated improved prognostication
of overall survival (OS) compared to the previous 7th
Ed. criteria.11,12 However, when considering selection cri-
teria for de-intensification of a locoregional treatment such
as radiotherapy (RT), it is important to understand factors
prognostic for locoregional failure (LRF), in addition to
OS. Although the AJCC 8th Ed. staging system has shown
prognostic utility regarding OS and distant failure, it is less
well-defined for predicting risk of LRF.11 This is likely
related to the observation that the predominant pattern of
failure in these patients following traditional therapies may
be distant.2,13,14 As such, the identification of effective
tools for prognostication of LRF in HPV-related OPSCC is
critical for appropriate implementation of treatment de-
intensification in this population.
The role of 18F-fluoro-2-deoxy-D-glucose positron emis-
sion tomography (18F-FDG PET) parameters as prognostic
factors in head and neck cancer has been extensively investi-
gated.15 Maximum standardized uptake value (SUVmax),
which represents maximal FDG SUV in the tumor, is the
earliest parameter that has been explored. However, the use
of SUVmax is limited by an inability to illustrate whole tumor
metabolic activity. As such, the prognostic value of SUVmax
in head and neck cancer is controversial.16–22
Recently, volumetric PET parameters, such as metabolic
tumor volume (MTV) and total lesion glycolysis (TLG), have
been heavily studied.23 MTV is the volume of tumor that
shows FDG avidity and TLG is a product of MTV and mean
SUV. Several studies have demonstrated the ability of MTV
and TLG to predict treatment outcomes in OPSCC.16–20,22,24–29
However, literature testing of its prognostic value specifically
in patients with HPV-related OPSCC patients and a ≤10 pack-
year smoking history is scarce. Given the need for and lack of
effective prognostic biomarkers for LRF in HPV-related
OPSCC, we sought to investigate the prognostic value of MTV
and TLG in this patient group.
2 | MATERIALS AND METHODS
2.1 | Patient population
We retrospectively reviewed electronic medical records of
539 OPSCC patients who received radiation therapy with or
without systemic therapy in the department of radiation oncol-
ogy at University of Michigan between 2005 and 2016. A
total of 299 HPV-related OPSCC patients with smoking his-
tory ≤10 pack-years were included. HPV-status was deter-
mined by detection of oncogenic HPV DNA or p16 protein in
tumor samples. Patients were excluded if they (1) had under-
gone surgery and/or chemotherapy before radiation, (2) had
been previously irradiated in the head or neck, (3) had distant
metastasis at the time of diagnosis, (4) did not have an analyz-
able pretreatment PET/CT scan, or (5) had a follow up time
of <6 months. After exclusion, 142 patients remained for
analysis. This study was conducted under an Institutional
Review Board-approved protocol (HUM00105976).
2.2 | Treatment regimen
At the time of diagnosis, staging procedures comprised his-
tory and physical examination, fiberoptic laryngoscopy, CT
scan of the neck, and 18F-FDG PET/CT scan. Some
patients underwent MRI of the neck if clinically indicated.
In this study, all patients were restaged according to the 8th
Ed. AJCC/Union Internationale Contre le Cancer (UICC)
TNM staging.
All patients received intensity-modulated radiation ther-
apy (IMRT), as previously described.30 IMRT dose prescrip-
tions were 70 Gy to gross disease and 56-64 Gy to other
at-risk areas, all in 35 fractions.
Concurrent systemic therapy consisted of weekly carbo-
platin (AUC1) and paclitaxel (30 mg/m2) in 93 patients
(65.5%), cetuximab in 30 patients (21.1%), and high-dose
cisplatin (100 mg/m2) every 3 weeks in 14 patients (9.9%).
Other regimens were weekly carboplatin (AUC2) in
2 patients and weekly paclitaxel (30 mg/m2) in 1 patients.
Two patients received definitive radiation alone because of
early stage and poor renal function.
After treatment, patients were routinely followed with
clinical examination every 2-3 months in the first 2 years,
every 4-6 months in the third to fifth year, then annually.
Post-treatment PET/CT scan was done at approximately
7-16 weeks after treatment for response evaluation. If there
was a suspicious residual disease in neck, neck dis-
section was conducted according to our institutional proto-
col. Regional failure was defined as disease recurrence in
neck >90 days after completion of RT.
2.3 | PET/CT scan
Attenuation-corrected pretreatment combined 18F-FDG
PET/CT scans of each patient were analyzed. Using infor-
mation from the image headers, acquisition parameters were
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determined. The majority of PET scans (82%) were acquired
on one of our institutional Siemens PET scanners (models:
1024, 1062, 1080, 1094 [TruePoint], Biograph 20, or Biograph
40). The remaining PET scans were acquired on a GE Medical
Systems Discovery ST/STE (14%) or Phillips Gemini/Guardian
(4%) system outside our institution. The heterogeneity of the
PET systems used is likely due to 12-year time span of the ret-
rospective study. Mean (SD) prescan blood glucose level
was 103 g/mL (23 g/mL) and time interval between FDG
and scan was 63 minutes (10 minutes).
2.4 | PET parameter analysis
Pretreatment PET/CT scans were retrospectively reviewed
by 2 radiation oncologists (T.C. and A.E. and/or M.M.) and
consensus volumes of interest (VOI) were manually con-
toured. The primary tumor and each metastatic lymph node
were contoured separately within the Contouring workspace
of our Eclipse radiation treatment planning system (Varian
Medical Systems, Palo Alto, California). Within this workspace,
raw intensity values were converted into SUV using the injected
activity, image acquisition time, and patient body weight. SUVs
within the VOIs were then exported and analyzed using in-
house software (Matlab, The Mathworks, Inc., Natick, Massa-
chusetts). SUVmax, MTV, and TLG were calculated as follows:
SUVmax was the maximum voxel intensity uptake in each VOI,
MTV was defined as the volume with intensity uptake greater
than 50% of SUVmax, and TLG was calculated by multiplying
MTV with the mean value of intensity uptake within the MTV.
For each patient, all PET parameters derived from the primary
tumor, combined metastatic lymph nodes (if node positive), and
total lesion were recorded.
2.5 | Statistical analysis
Treatment outcomes recorded in this study included failure-
free survival (FFS) and OS, measured from the end of
RT. Failures included LRF and distant metastasis, and sur-
vival times were censored at the time of first failure or date
of last follow-up. Associations between primary tumor and
nodal SUVmax, MTV, and TLG were explored using Pearson
correlation. For each clinical variable (age, T classification,
N classification, AJCC 8th Ed. group classification) and
PET parameter, association with the clinical outcomes was
explored using univariate Cox proportional hazards regres-
sion. Multivariate Cox proportional hazards models were
built using stepwise regression. For each step, significance
levels for both entry and stay were conservatively set at
0.10. To compare relative hazards among variables with dif-
ferent absolute units, the analysis was repeated using nor-
malized z scoring of input variables. Harrell's concordance
TABLE 1 Patient characteristics
Characteristic Mean (range)
Age (y) 58.9 (33-79)
Smoking history (pack-years) 1 (0-10)
Characteristic Number of patients (%)
Sex
Men 126 (88.7%)
Women 16 (11.3%)
Smoking status
Non-smoker 107 (75.4%)
Previous smoker 28 (19.7%)
Current smoker 7 (4.9%)
Tumor site
Base of tongue 91 (64.1%)
Tonsil 51 (35.9%)
T classification
1 31 (21.8%)
2 55 (38.7%)
3 23 (16.2%)
4 33 (23.2%)
N classification
0 10 (7.1%)
1 80 (56.3%)
2 29 (20.4%)
3 23 (16.2%)
8th edition group classification
I 57 (40.2%)
II 34 (23.9%)
III 51 (35.9%)
Concurrent systemic therapy
Carbo/taxol 93 (65.5%)
Cetuximab 30 (21.1%)
Cisplatin 14 (9.9%)
Carboplatin 2 (1.4%)
Taxol 1 (0.7%)
None 2 (1.4%)
FIGURE 1 Squared Pearson correlation (R2) and colorized heat map
depicting intercorrelation between all tested variables [Color figure can be
viewed at wileyonlinelibrary.com]
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index (c-index) was calculated for each fitted Cox model to
assess model performance.31 For the significant PET parame-
ters, tertile cutoff points (ie, 33rd and 66th percentile) were
calculated and used to stratify patients into 3 groups. Kaplan-
Meier survival curves were then generated to illustrate risk
stratification of univariate and multivariate models, and log-
rank P values were calculated. To investigate any heterogeneity
caused by different image acquisition devices, measured PET
parameters were stratified by machine manufacturer, and 2 sam-
ple t tests were calculated among groups. Two-sided P values
under .05 were considered significant. All analyses were per-
formed in R 3.4.1 (The R Foundation for Statistical Comput-
ing) and MATLAB R2017a (The MathWorks, Inc.). The
stepwise selection procedure was implemented using the My.
stepwise R package Ver. 0.1.0 and Kaplan-Meier curves were
generated using the survminer R package Ver. 0.4.2.
3 | RESULTS
3.1 | Patients and PET parameter characteristics
In total, 142 patients were available for analysis (Table 1).
The mean patient age (SD) was 58.9 (8.9) years. Most
of the population was men (88.7%). Nonsmoker patients
comprised 75% of the population, with the remainder <10
pack-years. In accordance with the 8th Ed. TNM staging,
the percentages of patients with stages I–III were 40.2,
23.9, and 35.9, respectively.
Median follow up time was 36 months. Ten of
142 patients suffered LRF. Two patients had a local recur-
rence as the first failure, 7 patients had a regional recurrence
as the first failure, and 1 patient had both local and regional
recurrence as the first failure. Distant recurrence as first
failure occurred in 16 patients. At the time of analysis, there
were 17 deaths.
Median (interquartile range [IQR]) SUVmax of the pri-
mary tumor, metastatic lymph nodes, and total lesion were
11.7 g/mL (8-15.6), 10.2 g/mL (6.4-13.3), and 13.3 g/mL
(9.7-17), respectively. Median (IQR) MTV of the primary
tumor, metastatic lymph nodes, and total lesion were 8.7 cc
(4.9-13.8), 6.6 cc (3.4-11.1), and 16.1 cc (11.2-22.5), respec-
tively. Median (IQR) TLG of the primary tumor, metastatic
lymph nodes, and total lesion were 51 g (29.6-114.4), 35 g
(16.6-89.3), and 115.8 g (68.1-190.2), respectively. No sig-
nificant difference by PET scanner manufacturer was found.
3.2 | Autocorrelation
The autocorrelations of PET and clinical variables are illus-
trated in Figure 1. In general, TLG and MTV were highly
correlated (Pearson R = 0.836, 0.865, 0.802 for primary,
nodal, and total lesion volumes, respectively). Primary tumor
SUVmax had a higher correlation with total lesion SUVmax
TABLE 2 Univariate analysis
LRFFS DMFS OS
HR* (95% CI) P c-index HR* (95% CI) P c-index HR* (95% CI) P c-index
Age 1.50 (0.79-2.88) .21 0.598 0.82 (0.50-1.35) .43 0.569 0.96 (0.58-1.58) .87 0.513
T classification 1.46 (0.77-2.76) .24 0.590 2.07 (1.21-3.54) .008 0.651 1.64 (1.02-2.64) .04 0.580
N classification 1.24 (0.65-2.33) .51 0.528 2.14 (1.30-3.51) .003 0.739 1.86 (1.11-3.13) .01 0.696
Group classification 1.20 (0.63-2.27) .58 0.541 4.33 (1.73-10.86) .002 0.764 4.71 (1.85-11.99) .001 0.753
SUVp 1.03 (0.56-1.90) .93 0.539 1.50 (0.97-2.30) .06 0.669 1.23 (0.78-1.93) .37 0.583
MTVp 1.70 (1.23-2.35) .001 0.509 1.24 (0.82-1.89) .30 0.569 1.33 (0.94-1.87) .10 0.558
TLGp 1.61 (1.16-2.23) .004 0.495 1.37 (0.96-1.95) .08 0.630 1.32 (0.94-1.85) .11 0.591
SUVn 1.61 (0.91-2.85) .10 0.683 1.25 (0.78-2.00) .35 0.618 1.13 (0.73-1.76) .58 0.580
MTVn 1.33 (0.80-2.19) .27 0.644 1.53 (1.08-2.15) .01 0.554 1.65 (1.20-2.26) .002 0.622
TLGn 1.47 (1.00-2.15) .05 0.686 1.61 (1.23-2.11) .001 0.589 1.52 (1.17-1.98) .002 0.624
SUVt 1.21 (0.67-2.16) .52 0.600 1.38 (0.89-2.15) .15 0.643 1.14 (0.73-1.78) .56 0.570
MTVt 1.79 (1.19-2.68) .005 0.707 1.61 (1.12-2.30) .01 0.683 1.80 (1.29-2.51) .001 0.728
TLGt 1.86 (1.29-2.70) .001 0.756 1.84 (1.35-2.50) <.001 0.745 1.68 (1.25-2.25) .001 0.711
Abbreviations: CI, confidence interval; c-index, concordance index; DMFS, distant metastasis-free survival; Group classification, 8th Edition American Joint Committee
on Cancer/Union Internationale Contre le Cancer (AJCC/UICC) staging; HR*, Cox proportional hazard ratio per normalized unit (z score); LRFFS, locoregional
failure-free survival; MTV, metabolic tumor volume; OS, overall survival; SUV, standardized uptake value; TLG, total lesion glycolysis. Subscripts: n, nodal tumor; p,
primary tumor; t, total lesion volume.
TABLE 3 Optimal cox models from stepwise multivariate analysis
HR* (95% CI) P c-index
Locoregional failure-free survival
TLGt 1.86 (1.29-2.70) .001 0.756
Distant metastasis free survival
Group classification 3.55 (1.39-9.07) .008 0.812
TLGt 1.45 (1.01-2.08) .04
Overall survival
Group classification 4.00 (1.56-10.27) .004 0.799
MTVt 1.51 (1.01-2.27) .04
Abbreviations: CI, confidence interval; HR*, Cox proportional hazard ratio per
z-score normalized unit; MTV, metabolic tumor volume, TLG = total lesion gly-
colysis. Subscript: t, total lesion (primary tumor + nodes).
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than did nodal SUVmax (Pearson R = 0.845 vs 0.548,
respectively). Primary tumor TLG was moderately correlated
with T classification (Pearson R = 0.575). The parameter
most correlated with overall classification was total lesion
TLG, but the correlation was weak (Pearson R = 0.406).
3.3 | Univariate analysis
Associations of clinical and PET parameters with LRF, DM,
and death were studied using univariate Cox analysis, with
results listed in Table 2. Total lesion MTV and TLG were
found to be associated with increased hazard for all
3 endpoints (LRF, DM, and death). The clinical T classifica-
tion, N classification, and overall group classification, in
addition to PET nodal MTV and nodal TLG, were associated
with increased hazard for DM and death. Neither SUVmax
nor age was associated with any of the clinical endpoints.
Total lesion TLG was the strongest predictor of LRF
(HR of 1.86 per SD increase and c-index of 0.756). Group
classification was the strongest predictor of DM and death
(HR of 4.33 and 4.71 per SD increase and c-index of 0.764
and 0.753, respectively). Notably, none of the clinical factors
were associated with LRF.
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FIGURE 2 Kaplan-Meier plots for each endpoint by stage [Color figure can be viewed at wileyonlinelibrary.com]
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FIGURE 3 Kaplan-Meier plots for each endpoint by total lesion total lesion glycolysis (TLG) [Color figure can be viewed at wileyonlinelibrary.com]
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3.4 | Multivariate analysis
In stepwise Cox regression for LRF, only total lesion TLG
was retained, generating equivalent univariate and optimal
multivariate LRF model. For DM and death, total lesion TLG
and total lesion MTV were individually selected and remained
statistically significant in 2-parameter models adjusted for
group classification (Table 3). Normalized proportional haz-
ard for DM and death, adjusting for classification were 1.45
and 1.51 for total lesion TLG and MTV, respectively.
3.5 | Kaplan-Meier analysis and tertile cutoffs
Figure 2 shows survival curves for all endpoints stratified by
the 8th Ed. AJCC/UICC TNM staging. Tertile thresholds (33rd
and 66th percentile values) for total lesion MTV and total lesion
TLG were 13.0/19.6 cc and 89/165 g, respectively. In Kaplan-
Meier analysis, stratification based on total lesion TLG was sta-
tistically significant in log-rank analysis for LRF (P < .01) and
DM (P = .03) but not for OS (P = .10) (Figure 3). Stratification
based on total lesion MTV was significant for LRF (P = .02)
and OS (P = .04) but not for DM (P = .16) (Figure 4).
4 | DISCUSSION
In the work described here, we found that total lesion TLG
and MTV correlated with LRF in patients with HPV-related
OPSCC and a ≤10 pack-year smoking history who received
definitive concurrent radiation and systemic therapy. This is
compared to the 8th Ed. AJCC/UICC TNM staging, which
showed no statistically significant association with LRF. In
contrast, TNM staging was the strongest predictor of DM and
OS, with total lesion volumetric PET parameters adding only
marginally significant prognostic information to staging.
Several studies have demonstrated prognostic value of
volumetric PET parameters in OPSCC.16–20,22,24–27 Mena
et al. retrospectively reviewed 105 HPV-related OPSCC and
found a statistically significant association between total
lesion TLG and event-free survival.18 Our results are concor-
dant with this observation. In comparison, the present work
reviewed the largest homogeneous patient population of
HPV-related OPSCC patients with ≤10 pack-year smoking
history and was the first to include the 8th Ed. AJCC/UICC
TNM staging for HPV-related OPSCC as a variable in multi-
variate analysis.
Our results showed total lesion TLG to be the strongest
predictor of LRF. Primary tumor volumetric PET parameter
was also significantly associated with LRF, although it dem-
onstrated poorer prediction performance than total lesion
PET parameters as reflected by a lower c-index. One meta-
analysis of the prognostic value of MTV/TLG in head and
neck cancer similarly showed that patients with high primary
tumor volumetric PET parameters had lower HRs for fail-
ures and death than patients with high total lesion volumetric
PET parameters.23 This is possible because the total lesion
represents the whole disease and provides more prognostic
information beyond primary tumor alone. In our study, there
was no statistically significant association between the 8th
Ed. AJCC/UICC TNM staging and LRF, and the addition of
volumetric PET parameters to the TNM staging appears to
improve prognostication of LRF beyond staging. Prospec-
tive studies are warranted to further investigate this finding.
Treatment de-intensification in patients with HPV-related
OPSCC and a minimal smoking history has been associated
with good treatment outcomes.6–9 The Eastern Cooperative
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FIGURE 4 Kaplan-Meier plots for each endpoint by total lesion metabolic tumor volume (MTV) [Color figure can be viewed at wileyonlinelibrary.com]
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Oncology Group (ECOG) conducted a phase II trial that used
complete clinical response to induction chemotherapy as selec-
tion criteria for reduction of radiation dose to 54 Gy in HPV-
related OPSCC patients.8 The study yielded excellent treatment
results in patients with a smoking history ≤10 pack-years with
2-year PFS and OS of 92% and 93%, respectively. A different
phase II study by Chera et al. investigated de-intensification of
concurrent chemoradiation in 44 patients with HPV-related
OPSCC, 95% of whom had ≤10 pack-year smoking history.6,7
The protocol consisted of reduced dose radiation therapy
(60 Gy) given concurrently with weekly low dose cisplatin
(30 mg/m2). Early results showed a high percentage (86%) of
pathological complete response evaluated at 9 weeks after
CCRT.6 More recently updated follow up demonstrated excel-
lent outcomes with 3-year local control, regional control, and
OS of 100%, 100%, and 95%, respectively.7
The de-intensification strategies described above have
relied on HPV-status, TNM stage, and smoking history to
determine eligibility. However, while these factors are prog-
nostic for OS, the utility of TMN stage and smoking history
in prognosticating LRF is less well defined.9,10 Given the
importance of LRF risk when considering patients for de-
intensification, tools for the accurate prognostication of LRF
in these patients are vital. Our study showed that total lesion
TLG/MTV could predict LRF and might help optimize treat-
ment intensity in these patients. For example, patients with a
very low predicted risk of LRF, based on these PET parame-
ters, may be appropriate for further radiation dose reduction,
which could further lower the probability of long-term com-
plications. Conversely, patients with a high predicted risk of
LRF may be poor candidates for de-intensification, despite
the presence of other favorable factors.
Significant associations between volumetric PET parame-
ters and DM/OS have been demonstrated in literature.19,20 Our
study similarly showed significant correlations between nodal
and total lesion TLG /MTV, and DM and OS in univariate anal-
ysis. However, the prognostic value of these parameters was
highly influenced by the 8th Ed. AJCC/UICC TNM staging, as
total lesion TLG and MTV were barely statistically significantly
associated with DM and OS in multivariate analysis, and added
little prognostic information to the staging.
The prognostic value of SUVmax in head and neck cancer
is controversial.16–22 One prospective study in 98 patients
with head and neck cancer showed no significant correlation
between pretreatment SUVmax and response to radiation
therapy.21 Our result also did not find significant correlation
between SUVmax and treatment outcomes.
There are several limitations to this study that require con-
sideration. First, the retrospective nature of this study possibly
contributed bias and confounding effects to relative risk esti-
mates. In addition, while the tertile thresholds used here were
convenient for dividing patients into 3 equal sized groups, the
absolute values of these are dependent on the specific
patient cohort. Alternative methods for selecting stratification
thresholds exist, such as maximum log-rank statistic and min-
imally selected P-value. However, due to the low event rate
and high propensity for false discovery due to multiple com-
parisons, these were not applicable in this work. Prospective
studies for determining optimal stratification thresholds based
on imaging parameters are warranted. Further, confounding
effects such as the evolution of treatment and imaging param-
eters over the wide time-course of this study may have
affected our results. Second, although a majority of our scans
came from a single manufacturer, differences in absolute out-
put across imaging devices was not fully characterized.
Lastly, there is some uncertainty associated with manual
delineation of tumors on 18FDG-PET scans. Although each
contour was reviewed by 2 radiation oncologists, it is possible
that slight inter-observer contour deviations could lead to dif-
ferent characterization and thus different PET parameters. We
believe that MTV and TLG may be more robust to these
changes in comparison to SUVmax.
5 | CONCLUSIONS
Volumetric PET parameters are uniquely prognostic of
locoregional failure-free survival in low-risk HPV-related
OPSCC and may be useful for directing de-intensification
strategies.
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